Effect of Yogurt With Polydextrose,L Acidophilus and B Lactis in Chronic Constipation
NCT ID: NCT01825434
Last Updated: 2013-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2010-02-28
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: Patients with constipation were randomly divided into two groups, Placebo Group (PG) and Treatment Group (TG), and had to eat 180 ml of unflavored yogurt every morning for 14 days. Those in the CG received only yogurt, while the TG received yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513). Expect that patients who took a combination of polydextrose has a decrease in the colonic transit time (CTT) when comparing initial and final transit time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
B. Lactis HN019 for Functional Constipation
NCT01463293
Effects of Probiotic Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Constipation.
NCT02189707
Exploring the Potential Benefits of Probiotic Yogurt
NCT06847919
Efficacy of Lacticaseibacillus Paracasei Strain Shirota on Clinical Manifestation of Functional Constipation in Mexican Adults
NCT06432608
Effect of an 8-week Bifidobacterium Lactis HN019 Supplementation on Functional Constipation
NCT04231162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Group
yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513) 1 time per day, for 30 days.
yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019
NCFM Group
Placebol group
regular yogurt, 1 time per day for 30 days.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019
NCFM Group
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* agachan between 10 and 20
* bowel transit time with ingestion of 24 radiopaque markers (Sitzmarks) and retention of 80% of them on day 5
Exclusion Criteria
* antidepressant users
* normal colonic
* transit time (24 hrs or less) as well as higher than 96 hours were
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Campinas, Brazil
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Claudio Saddy Rodrigues Coy
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claudio SR Coy, Ph.D
Role: STUDY_CHAIR
University of Campinas, Brazil
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Campinas
Campinas, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CE 454/2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.